Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00644696 · ClinicalTrials.gov registry record · Phase 1
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00644696 is a Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 18 participants.
The verdict
NCT00644696, a Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This Phase One pediatric trial seeks to take advantage of the susceptibility of neuroblastoma to proteasome inhibitors, proven in vitro, along with the proven in vitro synergy of bortezomib with irinotecan and the successful Phase One pediatric trials of bortezomib to create a treatment using these two drugs in combination to treat refractory/recurrent neuroblastoma in children and young adults 25 and under.
Interventions
- DRUG Irinotecan and Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00644696
The ClinicalTrials.gov registry entry for NCT00644696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irinotecan and Bortezomib is the first listed.
NCT00644696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00644696 about?
NCT00644696 is a clinical study titled "Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma". This Phase One pediatric trial seeks to take advantage of the susceptibility of neuroblastoma to proteasome inhibitors, proven in vitro, along with the proven in vitro synergy of bortezomib with irinotecan and the successful Phase One pediatric trials of bortezomib to create a treatment using these ...
What is the current status of trial NCT00644696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2008-04. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00644696?
The interventions under investigation include: Irinotecan and Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00644696?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.